ATG10rs1864182 was also shown to serve as biomarker for primary or acquired resistance to chemotherapy when using gefitinib (an epidermal growth factor receptor (EGFR)-TKI drug) in advanced lung adenocarcinoma patients with EGFR mutations [49]. The gene discussed is EGFR; the disease is lung adenocarcinoma.